Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Clinical trial NCT02885766 · UNKNOWN
Trial details
- NCT number
- NCT02885766
- Sponsor
- Fusion Pharma LLC
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-01
- Primary completion
- 2018-06-01
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.